Peripheral Blood Markers Predict Prognosis and Treatment-Related Adverse Events of Stage IB–IVA Cervical Squamous Cell Carcinoma Treated with Chemoradiotherapy Combined with Hyperthermia

Cervical cancer remains a formidable threat to women's health, particularly in regions where access to advanced screening and vaccination is limited. For tumors that have grown large or spread beyond the cervix but have not yet reached distant organs, the standard medical approach involves a powerful combination of radiation therapy and chemotherapy, known as concurrent chemoradiotherapy. This treatment aims to destroy cancer cells by damaging their genetic material while using drugs to make the cells more vulnerable to radiation. However, even with this aggressive strategy, the outcome is not guaranteed for every patient. Some individuals experience the disease returning, while others suffer severe side effects that can halt their treatment. To improve care, doctors need better ways to predict who is most likely to survive and who is most likely to struggle with the toxicity of the therapy. Researchers are increasingly looking at simple blood tests taken before treatment begins, hoping to find hidden clues within the body's own immune cells and chemical markers that can forecast these outcomes.

A team of researchers at the Affiliated Hospital of Chengde Medical University set out to investigate these possibilities in a specific group of patients. They focused on 193 women diagnosed with stage IB through IVA cervical squamous cell carcinoma, a type of cancer that makes up the vast majority of cervical cancer cases. These patients received the standard chemoradiotherapy regimen, but with an added layer of treatment: deep microwave hyperthermia. This technique involves heating the tumor tissue to a temperature that damages cancer cells without harming the surrounding healthy tissue, effectively making the radiation and chemotherapy work better. The researchers followed these women for a median of 40.6 months to see how long they survived without the cancer returning and to track how many experienced significant side effects. Their goal was to determine if specific, easily measurable factors in the patients' blood could predict who would do well and who would face difficulties.

The results of this long-term observation were encouraging regarding the treatment's overall effectiveness. Over the course of the study, the three-year survival rate for the group was 81.34%, and the rate of remaining free from disease progression was 81.27%. However, the study revealed that not all patients had the same odds. The researchers found that two specific factors present before treatment began were the strongest predictors of a poorer outcome. The first was the stage of the cancer at diagnosis, specifically how far it had spread according to the International Federation of Gynecology and Obstetrics classification system. The second was the level of a protein called squamous cell carcinoma antigen in the blood. Patients who had higher levels of this protein, specifically above 4 nanograms per milliliter, faced a significantly higher risk of the cancer returning or causing death, regardless of their age or other health conditions. This confirmed that the antigen level is a reliable indicator of the disease's aggressiveness.

While the antigen level helped predict survival, the researchers discovered a different blood marker that was crucial for predicting safety. They examined the ratio of lymphocytes, which are infection-fighting white blood cells, to monocytes, a type of white blood cell involved in inflammation. They found that patients with a lower ratio of these cells were much more likely to suffer from treatment-related adverse events, such as a dangerous drop in blood cell counts known as myelosuppression. Specifically, patients whose ratio was four or lower faced a significantly higher risk of toxicity. This suggests that the body's balance of immune cells before treatment starts can signal how well a patient will tolerate the rigors of chemoradiotherapy combined with heat therapy. In contrast, other common blood markers and tumor indicators did not show a clear link to either survival or side effects in this specific group.

The study also provided a detailed look at the side effects themselves. More than half of the patients experienced some form of treatment-related adverse event, with the most common being a suppression of the bone marrow's ability to produce blood cells. This occurred in 91 cases, ranging from mild to severe. The researchers noted that while the treatment was effective for the majority, the risk of these side effects was not random; it was closely tied to the patient's initial blood profile. By identifying patients with a low lymphocyte-to-monocyte ratio before they started therapy, doctors could potentially prepare better supportive care, such as using growth factors to boost blood cell production, to ensure the treatment could continue safely.

This research, conducted as a retrospective review of medical records, offers a practical tool for clinicians. It highlights that simple blood tests taken before treatment can provide a clear picture of both the likely course of the disease and the potential risks of the therapy. The findings confirm that the stage of the cancer and the level of squamous cell carcinoma antigen are independent predictors of survival, while the balance of specific white blood cells serves as a warning sign for treatment toxicity. Although the study was limited to a single hospital and requires validation in larger groups, it suggests that integrating these blood markers into routine care could help doctors tailor treatment plans more precisely, ensuring that patients receive the right level of support to survive and thrive through their therapy.